Multi-stage oral drug controlled-release system

• US 20030180362A1
• Filed: 02/03/2003
• Published: 09/25/2003
• Est. Priority Date: 02/01/2002
• Status: Abandoned Application

• Current Assignee: AmorePacific Group, Inc.
• Original Assignee: AmorePacific Group, Inc.
• Inventors: Bae, Joon Ho, Park, Jin Woo, Kim, Jung Ju
• Application Number:
  US10/357,821
• Publication Number:
  US 20030180362A1
• Time in Patent Office: Days
• US Class Current: 424/470
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 31/554 having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/282 Organic compounds, e.g. fats
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

A multi-stage oral drug controlled-release system is disclosed, as well as a preparation for maintaining the drug blood concentration at a desired level for a prolonged time. The system operates by releasing the drug at a constant rate through stepwise control of drug release following administration of the preparation. More specifically, the multi-stage oral drug controlled-release system involves the stepwise release of drug-containing granules from an inner matrix, which is surrounded by a coating or release-modifying layer. The granules contain an active drug and a carrier material in size of 0.1˜1 mm. The carrier material is hydrophobic when the drug has a water-solubility of 1 mg/ml or more, and is hydrophilic when the drug has a water-solubility of less than 1 mg/ml. The inner matrix, in which the drug-containing granules are embedded, is formed from swelling and erodible polymer(s) and swelling-regulating material(s). The release-modifying layer is composed of a hydrophobic release-modifying polymer, a hydrophilic release-modifying polymer, pH-dependent release-modifying polymer or mixtures thereof.

Claims

1. A controlled-release oral preparation characterized in that release of granules from matrix and drug release from the granules are conducted in stepwise way, wherein the preparation comprises:

(a) granules comprising a drug and a carrier material in size of 0.1˜

1 mm, said carrier material is hydrophobic material in case of drug with water-solubility of 1 mg/ml or more and said carrier material is hydrophilic material in case of drug with water-solubility of less than 1 mg/ml;

(b) a matrix in which the granules are embedded, comprising swelling and erodible polymer and swelling-regulating material; and

(c) a release-modifying layer comprising hydrophobic release-modifying polymer, hydrophilic release-modifying polymer, pH-dependent release-modifying polymer or a mixture thereof.

2. The controlled-release oral preparation in claim 1, wherein 50 to 100% of the drug is present within the granules, and the remaining drug exists within the matrix or the release-modifying layer, or within the matrix and the release-modifying layer in directly dispersed form.

3. The controlled-release oral preparation in claim 1, wherein the drug has a water-solubility within range from 1 mg/ml to 100 mg/ml, and the granules containing the drug is prepared by wet granulation.

4. The controlled-release oral preparation in claim 1, wherein the drug has a water-solubility of at least 100 mg/ml, and the granules containing the drug is prepared in granular form by dispersing the drug in fusion of granules components.

5. The controlled-release oral preparation in claim 1, wherein the drug has a water-solubility of less than 1 mg/ml, and the granules containing the drug is prepared by solid dispersion method.

6. The controlled-release oral preparation in claim 1, wherein the hydrophobic material is at least one selected from the group consisting of fatty acids, fatty acid esters, fatty acid alcohols, fatty acid mono-, di-, tri-glycerides, waxes, hydrogenated castor oil and hydrogenated vegetable oil.

7. The controlled-release oral preparation in claim 6, wherein the fatty acid alcohol is at least one selected from the group consisting of cetostearyl alcohol, stearyl alcohol, lauryl alcohol and myristyl alcohol;

fatty acid ester is at least one selected from the group consisting of glyceryl monostearate, glycerol monooleate, acetylated monoglyceride, tristearin, tripalmitin, cetyl ester wax, glyceryl palmitostearate and glyceryl behanate; and

wax is at least one selected from the group consisting of beeswax, carnauba wax, glyco wax and castor wax.

8. The controlled-release oral preparation in claim 1, wherein the hydrophilic material is selected from polyalkylene glycol, carboxyvinyl hydrophilic polymer or a mixture thereof, and the drug is solid-dispersed in said hydrophilic polymer.

9. The controlled-release oral preparation in claim 1, wherein the swelling and erodible polymer is at least one selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethylcellulose, polyethylene oxide, sodium alginate, povidone, polyvinyl alcohol and sodium carboxymethylcellulose.

10. The controlled-release oral preparation in claim 1, wherein said swelling-regulating material is at least one selected from the group consisting of cross-linked sodium carboxymethylcellulose and cross-linked polyvinylpyrrolidone.

11. The controlled-release oral preparation in claim 1, wherein said hydrophobic release-modifying polymer used for the formation of release-modifying layer, is at least one selected from the group consisting of ethylcellulose, shellac and ammonio methacrylate copolymer;

said hydrophilic release-modifying polymer is at least one selected from the group consisting of hydroxyalkylcellulose and hydroxypropylalkylcellulose; and

said pH-dependent release-modifying polymer is at least one selected from the group consisting of hydroxyalkylcellulose phthalate, hydroxyalkylmethylcellulose phthalate, cellulose acetyl phthalate, sodium cellulose acetate phthalate, cellulose ester phthalate, cellulose ether phthalate, and anionic copolymer of methacrylic acid with methyl or ethyl methacrylate.

12. The controlled-release oral preparation in claim 1, wherein said release-modifying layer is 1 to 20% by weight to total weight of matrix, and the granules containing the drug reach 50 to 80% by weight to total weight of the preparation.

13. The controlled-release oral preparation in claim 1, wherein the drug is selected from:

therapeutic agents for aconuresis of oxybutynin, tolterodine and therapeutically equivalent salts thereof;

calcium channel blockers of nifedipine, verapamil, isradipin, nilvadipin, flunarizine, nimodipine, diltiazem, nicardipine, nisoldipin, felodipin, amlodipin, cinarizin and pendilin and pharmaceutically acceptable derivatives thereof;

beta adrenergic antagonists of propranolol, metoprolol and pharmaceutically acceptable derivatives thereof;

angiotensin-converting enzyme inhibitors of captopril, enalapril, ramipril, fosinopril, altiopril, benazepril, libenzapril, alacepril, cilazapril, cilazaprilat, perindopril, zofedopril, lisinopril, imidapril, spirapril, rentiapril, delapril, alindapril, indalapril, quinalapril and therapeutically equivalent salts thereof;

non-steroidal anti-inflammatory agents of ketorolac, ketoprofen, benoxaprofen, caprofen, flubiprofen, fenoprofen, suprofen, fenbufen, ibuprofen, indoprofen, naproxen, miroprofen, oxaprozine, pranoprofen, pirprofen, thiaprofenic acid, fluprofen, alminoprofen, bucloxic acid, alclofenac acematacin, aspirin, indomethacin, ibufenac, isoxepac, profenac, fentiazac, clidanac, oxpinac, sulindac, tolmetin, zomepirac, zidometacin, tenclofenac, tiopinac, mefenamic acid, flufenamic acid, niflumic acid, meclofenamic acid, tolfenamic acid, diflufenisal, isoxicam, sudoxicam and therapeutically equivalent salts thereof;

therapeutic agents for respiratory disorders of theophylline, salbutamol, aminophylline, dextromethorphan, pseudoephedrine and therapeutically equivalent salts thereof;

analgesics of tramadol, acetaminophen, morphine, hydromorphone, oxycodone, propoxyphene and therapeutically equivalent salts thereof;

psychoneural drugs of fluoxetine, paroxetine, buspirone, carmabazepine, carvidopa, levodopa, methylphenidate, trazodone, valproic acid, amitriptyline, carbamazepine, ergoloid, haloperidol, lorazepam and therapeutically equivalent salts thereof;

antibiotics of azithromycin dihydrate, cepha antibiotics, clarithromycin, doxycycline, nitrofurantonin and therapeutically equivalent salts thereof;

antihyperlipidemic agent of bezafibrate, fenofibrate, ethofibrate, lovastatin and therapeutically equivalent salts thereof;

antidiabetic agent of glyburide, glipizide, metformin and therapeutically equivalent salts thereof; and

cyclobenzaprin, favotidin, nizatidine, propafenone, clonazepam, hyoscyamine, diphenhydramine, olistat, doxazosin and therapeutically equivalent salts thereof.

14. The controlled-release oral preparation in claim 1, wherein the drug is released in zero-order over at least 8 to 24 hr upon the administration of the preparation.

15. The controlled-release oral preparation in claim 1, wherein by erosion of the surface of matrix, 0 to 20% of total granules is released over 0 to 4 hr, 0 to 50% is released over 0 to 8 hr, 0 to 70% is released over 0 to 16 hr, and 0 to 100% is released over 0 to 24 hours.